Home > Formulary : Paediatric > Paediatric Chapters > 8. Malignant Disease and Immunosuppression >
BNSSG Paediatric Joint Formulary
8.1 Immune system
Last edited: 31-01-2024
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
8.1.1 Immune system disorders and transplantation
Antimetabolites
Azathioprine (oral & parenteral)
Azacitidine (parenteral)
- Via NHS England for myelodysplastic syndromes
Calcineurin Inhibitors and Related Drugs
Ciclosporin (oral & parenteral)
Sirolimus (oral)
- Renal Consultant, haematology, BMT physician use only
Tacrolimus (oral & parenteral)
- Prescribe by brand
- NICE TA482 Immunosuppressive therapy for kidney transplant in children and young people
Immunoglobulins
Antithymocyte globulin (ATG) (rabbit)
- Renal, Immunology, Haematology and BMT Consultant use only, as per Trust protocol
Antithymocyte globulin (ATG) (horse)
Monoclonal Antibodies (Anti-lymphocyte)
Basiliximab (parenteral)
- Basiliximab may only be prescribed in line with the Renal Unit protocol.
- NICE TA482 Immunosuppressive therapy for kidney transplant in children and young people
Purine Synthesis Inhibitors
Mycophenolate mofetil (oral & parenteral)
- NICE TA482 Immunosuppressive therapy for kidney transplant in children and young people.
- Also used for immunomodulation / immunosuppression (unlicensed) under the supervision of Specialists in:
Neurology - see Chapter 10
Rheumatology - see Chapter 10
Gastroenterology - see Chapter 1
Ophthalmology- see Chapter 11
Renal (non-transplant use)
Dermatology - see Chapter 13
Respiratory
IV and oral in BMT specialist use
Alternative to mycophenolate mofetil:
Mycophenolic acid (as mycophenolate sodium) (oral)
Anti-lymphocyte Monoclonal Antibodies
Alemtuzumab (parenteral)
- Pre-transplant immunosuppression and CLL according to NHS England guidance only
- Treatment of relapsed or refractory chronic lymphocytic leukaemia
- 1st line treatment of chronic lymphocytic leukaemia in patients with 17p deletion
- 2nd line treatment of chronic lymphocytic leukaemia in patients with 17p deletion previously treated with chemotherapy but not alemtuzumab
- 1st line treatment of T-cell prolymphocytic leukaemia
- 2nd line treatment of T-cell prolymphocytic leukaemia
8.1.2 Other
Canakinumab (TLS Red)
Anakinra (TLS Red)